MK-677

MK-677 (Ibutamoren): A Scientific Review of the Oral Growth Hormone Secretagogue

Based on peer-reviewed literature — see References. Last updated: May 2026.

The Short Version

MK-677 is one of the more unusual compounds in this review series, because for once the story isn't "interesting preclinical data with no human trials." It's almost the opposite: substantial human clinical trial data going back nearly three decades, including a well-designed 2-year placebo-controlled study in older adults published in Annals of Internal Medicine, FDA Orphan Drug Designation, and pharmaceutical industry development that reached late-stage clinical trials before getting set aside.

The compound is also one of the most heavily marketed "research peptides" in the bodybuilding and longevity space — which is itself a piece of misdirection, because MK-677 isn't a peptide. It's a small, orally active, non-peptide molecule developed by Merck in the early 1990s. The mainstream framing as a "peptide" alongside BPC-157 and similar compounds is a marketing convenience, not a chemical fact.

The pharmacology is real and well-characterized. MK-677 is a selective agonist of the ghrelin receptor (GHSR-1a) — the same receptor that endogenous ghrelin activates, and the same target hit by injectable peptide secretagogues like ipamorelin. Activating that receptor stimulates the pituitary to release growth hormone (GH), which then stimulates the liver to produce IGF-1. The result is a sustained elevation of both GH and IGF-1 levels — the two hormones that drive most of the anabolic, body composition, and recovery effects people associate with growth hormone therapy. But unlike injectable HGH, MK-677 preserves the natural pulsatility of GH secretion, which is generally considered a feature.

In healthy older adults over 12 months, MK-677 at 25 mg/day increased fat-free mass by approximately 1.1 kg, raised GH and IGF-1 to young-adult levels, and was generally well-tolerated.^[2] That sounds like a clear win. The catch is that the same trial showed:

• No improvement in muscle strength or physical function despite the increased fat-free mass
• Worsening of insulin sensitivity (Quicki index decreased, fasting glucose rose, HbA1c rose)
• Cortisol elevation of approximately 47 nmol/L
• Mild lower extremity edema in some participants
• Appetite increase and weight gain beyond just lean tissue

That's the central tension of MK-677: it does what it's supposed to do hormonally, but the downstream functional benefits are smaller than the hormone numbers would suggest, and the metabolic costs are real.

A second important data point is rarely discussed in the wellness press: a separate trial in older adults with hip fracture, sponsored by Merck, showed increased adverse events (including congestive heart failure) at MK-677-equivalent doses. This trial was a major factor in Merck's eventual decision not to pursue further development.^[5]

Origin: Merck's Search for an Oral GH Therapy

The MK-677 story starts in a place that's easy to forget: the early 1990s pharmaceutical race to find an oral alternative to injectable growth hormone.

By that point, recombinant human growth hormone (rhGH) was an established but inconvenient therapy. It worked for growth hormone deficiency, certain pediatric conditions, and (controversially) HIV-associated wasting. But it required daily subcutaneous injection, was expensive, produced supra-physiologic single-pulse exposure rather than the natural pulsatile pattern, and had its own side effect profile. The market pressure for an oral GH alternative was substantial.

Merck's approach was to find a small molecule that would stimulate endogenous GH secretion rather than supplement GH directly. The biology suggested this should be feasible: there was a known peptide called GHRP-6 (growth hormone releasing peptide-6) that powerfully stimulated GH release through a then-unidentified receptor. Merck's medicinal chemistry program aimed to find a non-peptide small molecule that activated the same receptor with similar potency.

The Patchett et al. paper in PNAS in 1995 reported the result: L-163,191, later renamed MK-677, a spiropiperidine compound that selectively activated what would later be identified as the ghrelin receptor (GHSR-1a).^[1] The compound was orally active, long-acting, and produced robust GH stimulation.

What happened next is the long, slow, mixed-results clinical development program. Phase 1 and 2 trials proliferated through the late 1990s and 2000s. The compound was tested in healthy young adults, healthy elderly adults, GH-deficient children, GH-deficient adults, obese subjects, hip fracture patients, and several other populations. The results were consistent on hormonal effects (GH and IGF-1 rise to young-adult levels). The results on clinical benefits and safety were inconsistent enough that Merck eventually halted development.

In 2017, LUMOS Pharma acquired rights to develop MK-677 as LUM-201 specifically for pediatric growth hormone deficiency. Both FDA and EMA granted Orphan Drug Designation. As of mid-2026, LUM-201 remains in clinical development for that specific indication. The broader development for adult muscle wasting, frailty, sarcopenia, and obesity has not been pursued by a major pharmaceutical company since Merck's withdrawal.

How It Works

The ghrelin receptor and growth hormone biology

Growth hormone secretion from the pituitary is regulated by a competing-signal system. GHRH (growth hormone-releasing hormone) from the hypothalamus stimulates GH release. Somatostatin inhibits it. The balance between these two signals — together with ghrelin from the stomach — produces the characteristic pulsatile pattern of GH secretion, with the largest pulses occurring during slow-wave sleep. For broader context on this hormonal axis and related compounds, see the Endocrine Research category.

Ghrelin acts on the growth hormone secretagogue receptor type 1a (GHSR-1a) — a G-protein-coupled receptor expressed in the hypothalamus, pituitary, and various peripheral tissues. Activation of GHSR-1a has multiple effects:

• Stimulates GHRH release
• Suppresses somatostatin release
• Directly activates pituitary somatotrophs
• Promotes appetite (ghrelin is the "hunger hormone")
• Affects sleep architecture (favors slow-wave sleep)
• Modulates insulin sensitivity (negatively)
• Affects mood and reward circuits

MK-677 is a selective non-peptide agonist of this receptor — pharmacologically a "ghrelin mimetic." A 2021 cryo-EM structure published in Nature Communications (Liu et al.) showed exactly how MK-677 binds GHSR-1a, illuminating the structural basis of its activity.^[7]

What activation does

After MK-677 binds GHSR-1a, the downstream effects mirror what happens with elevated endogenous ghrelin:

• GH pulse amplitude increases. The natural pulsatile pattern is preserved (this is one of the compound's distinguishing features), but the peaks are higher.
• IGF-1 rises. The liver responds to the elevated GH exposure by increasing IGF-1 production. IGF-1 mediates many of GH's downstream effects on tissues.
• Appetite increases. This is direct GHSR-1a activation, separate from the GH/IGF-1 axis.
• Slow-wave sleep increases. This is documented in multiple trials, particularly relevant since GH peaks naturally during slow-wave sleep.
• Cortisol rises modestly. GHSR-1a activation increases ACTH release.

The pulsatility argument

One pharmacological point worth understanding clearly, because it gets repeated as a marketing line: MK-677 does preserve the natural pulsatile pattern of GH secretion, unlike injectable rhGH which produces a single high-amplitude pulse after each injection.

Pulsatility matters for several reasons. It's how the body's tissue responses are calibrated to GH — receptors desensitize after sustained exposure but reset between pulses. It's also how IGF-1 production gets regulated, and how the GH/IGF-1 axis interacts with insulin sensitivity, glucose homeostasis, and other systems.

Is preserved pulsatility actually clinically advantageous over rhGH? The honest answer is "probably, but not in a way that's been definitively demonstrated." The studies that would directly compare clinical outcomes (long-term, head-to-head) haven't been done. The argument is mechanistic plausibility rather than measured advantage.

Human Evidence: The Nass 2008 Trial

This is the cornerstone study, and it's worth examining closely because it's the strongest human dataset and most representative of what MK-677 actually does in people.

Design

Two-year, double-blind, randomized, placebo-controlled, modified-crossover trial in 65 healthy older adults (ages 60-81). 43 randomized to MK-677 25 mg daily; 22 to placebo. Conducted at the University of Virginia and three other US sites. Funded by NIH and Merck (Merck provided the drug).^[2]

Primary findings (12 months)

Hormonal effects:

• GH levels increased 1.8× from baseline
• IGF-1 levels increased 1.5×, reaching young-adult range
• Pulsatile pattern of GH secretion preserved

Body composition:

• Fat-free mass: +1.1 kg in MK-677 vs -0.5 kg in placebo (P<0.001)
• Body cell mass: +0.8 kg in MK-677 vs -1.0 kg in placebo
• Total body water and intracellular water increased (consistent with anabolic effects)
• Limb fat increased more in MK-677 group (+1.1 kg vs +0.24 kg)
• Body weight increased 2.7 kg in MK-677 group vs 0.8 kg in placebo
• Abdominal visceral fat: no significant difference between groups
• Total fat mass: no significant difference between groups

Functional outcomes:

• Increased fat-free mass did not result in changes in strength or function.

This last point is critical and often glossed over. The compound added muscle tissue but didn't make participants meaningfully stronger or better-functioning. For an indication targeting frailty in older adults, this is a meaningful limitation.

Metabolic effects:

• Fasting blood glucose increased
• HbA1c increased
• Quicki index of insulin sensitivity decreased
• LDL cholesterol decreased slightly
• Cortisol rose (+47 nmol/L)

At 24 months (subset analysis):

• Hormonal and body composition effects persisted
• Fasting glucose changes had normalized

Adverse effects:

• Increased appetite (most common)
• Transient, mild lower-extremity edema
• Muscle pain
• No significant increase in serious adverse events
• No newly detected malignancies in the trial period

What this trial actually shows

A nuanced reading: MK-677 reliably does what its mechanism predicts. GH and IGF-1 go up. Body composition shifts toward more lean tissue. Most participants tolerate it adequately.

But the functional payoff is smaller than the body composition numbers suggest, the metabolic costs (insulin sensitivity in particular) are real, and the trial wasn't designed to capture longer-term outcomes that matter most for an aging population.

Other Human Trials

The Nass 2008 trial is the most-cited, but several other human studies exist:

• Svensson et al. 1998 (obesity, 2-month): GH secretion, fat-free mass, and energy expenditure all increased in obese adults.
• GH-deficient adults: MK-677 raised GH and IGF-1, though effects were generally less robust than in GH-replete subjects.
• GH-deficient children (the LUM-201 indication): A subset of pediatric GHD patients respond to MK-677, leading to the orphan drug designation and ongoing LUMOS Pharma development program. The trick is identifying which children are "secretagogue-responsive" — work on predictive biomarkers continues.
• Hip fracture recovery: This is the trial that contributed to Merck halting broader development. MK-677 in older hip fracture patients was associated with increased adverse events including congestive heart failure. The compound's fluid retention effect, while typically mild in healthier populations, became more consequential in patients with reduced cardiovascular reserve.
• Catabolic states / cancer cachexia: Some small studies; results mixed.

The cumulative human safety database for MK-677 is substantial by the standards of compounds in this review series — likely several thousand patient-exposures across two decades of clinical development.

Regulatory Status

The Orphan Drug Designation is worth understanding clearly. ODD is granted to compounds being developed for rare conditions (in the US, fewer than 200,000 affected patients). It provides regulatory and commercial incentives for development but is not an approval. LUM-201 is in ongoing clinical development; whether it will receive full FDA approval for pediatric GHD is still pending.

The WADA prohibition predates the structural identification of MK-677 as a non-peptide — anti-doping classification follows mechanism, not chemistry. The compound elevates GH and IGF-1, which is what S2 covers. Recent hair-testing methods can detect MK-677 use months after discontinuation, with quantitative LC-MS/MS able to identify both single-dose exposure (1.3 pg/mg at 4 weeks post-exposure) and chronic use (224 pg/mg in a user taking 60×10mg over 90 days).^[8]

Safety: What's Documented

This is where MK-677 differs from most compounds in this review series — there's actually a substantial documented safety profile to discuss, not just theoretical concerns.

Insulin sensitivity decline

This is the most consistently documented metabolic effect. Across multiple trials:

• Fasting glucose rises
• HbA1c rises
• Insulin sensitivity indices (Quicki, HOMA-IR) decline
• Effects are dose-dependent

The mechanism is clear: GH directly antagonizes insulin action at the cellular level, and chronic GH elevation produces measurable insulin resistance. This is a known property of all growth hormone-elevating therapies, including injectable rhGH.

For an otherwise metabolically healthy young adult, the effect may be modest and reversible. For someone with prediabetes, type 2 diabetes, metabolic syndrome, or strong family history thereof, the effect is more consequential.

Fluid retention

GH elevation produces sodium and water retention. In trials, this manifested as mild lower-extremity edema in some participants. For most users this is cosmetic. For users with congestive heart failure, kidney disease, or compromised cardiovascular reserve, it can be clinically significant — which is exactly what surfaced in the Merck hip fracture trial.

Cortisol elevation

GHSR-1a activation increases ACTH and therefore cortisol. The +47 nmol/L rise documented in Nass 2008 is modest but real and sustained. Chronic mild cortisol elevation has implications for glucose tolerance (worsens insulin sensitivity further), bone health (decreases bone mineral density over time), immune function, and mood.

Increased appetite and weight gain

The body composition effect of MK-677 is partly anabolic (real muscle tissue gain) and partly accretive (increased food intake leading to general weight gain, including fat). For users targeting body recomposition rather than absolute mass gain, this is a counterproductive effect.

Potential cardiovascular concerns

Two threads converge:

• Fluid retention contributes to volume load on the heart
• The Merck hip fracture trial showed increased CHF events at active doses

For young, healthy adults the cardiovascular risk profile is probably modest. For older adults, anyone with existing cardiovascular disease, or those with reduced ejection fraction, the risk is substantive.

Cancer biology

GH and IGF-1 are growth-promoting hormones. There's a substantial epidemiological literature linking elevated IGF-1 to increased risk of certain cancers (particularly prostate, breast, colorectal). Whether the magnitude of IGF-1 elevation from MK-677 (~1.5×, into young-adult range) translates to clinically meaningful cancer risk is uncertain. The trials are too short and underpowered for cancer endpoints. The Nass 2008 trial reported no newly detected malignancies during the study period, but a 2-year trial in 65 participants cannot detect modest cancer risk changes.

For anyone with personal or family history of hormone-sensitive cancers, this is a meaningful unresolved question.

Other documented effects

• Numbness and tingling (peripheral nerve effects, occasionally reported)
• Mild aches and joint pains (similar to rhGH)
• Vivid dreams (related to slow-wave sleep changes)
• Lethargy in some users
• Mild blood pressure changes

Common Misconceptions

"It's a peptide."

It isn't. MK-677 is a small spiropiperidine molecule developed by Merck's medicinal chemistry program. The frequent grouping with BPC-157, TB-500, and other actual peptides on vendor websites is incorrect labeling. Pharmacokinetically, structurally, and metabolically, MK-677 is an orally active small molecule.

"It's safer than injectable HGH because it works through your own pituitary."

This is partially true and substantially misleading. MK-677 does preserve natural GH pulsatility, which has theoretical advantages over single-pulse exogenous HGH. But the downstream effects on insulin sensitivity, fluid retention, IGF-1 elevation, and cortisol are largely the same as with exogenous GH, because the elevated hormones produce the same tissue effects regardless of source. "Endogenous" doesn't equal "safer."

"It builds muscle."

It produces measurable increases in fat-free mass. Whether that translates to functional muscle (in the sense of increased strength and athletic performance) is less clear. The Nass 2008 trial specifically documented increased fat-free mass without corresponding increases in strength or physical function. Some of the "muscle" gain may be intracellular water and other non-contractile tissue.

"There's lots of research, so it must be safe."

There is substantial research, and that research documents real safety concerns: insulin resistance, fluid retention, cortisol elevation, and the Merck hip fracture trial signal. "Well-studied" doesn't mean "shown to be safe" — in MK-677's case, the studies have shown specific, predictable adverse effects that were significant enough to halt mainstream pharmaceutical development.

"It's an SARM."

It isn't. SARMs (Selective Androgen Receptor Modulators) work through androgen receptors and affect testosterone-related pathways. MK-677 works through the ghrelin receptor and affects GH/IGF-1. The compounds are frequently sold by the same vendors and stacked by users, but mechanistically they're unrelated.

"It restores you to young adult hormone levels, which must be optimal."

The Nass 2008 study showed MK-677 raises older adults' GH/IGF-1 to young-adult ranges. Whether achieving young-adult hormone levels in older bodies is optimal is a separate question. The decline of GH with age may be physiologic adaptation rather than pure deficiency, and "more hormone is better" doesn't necessarily hold.

Frequently Asked Questions

What's the current status of LUM-201?

LUMOS Pharma continues developing MK-677 (as LUM-201) specifically for pediatric growth hormone deficiency. Phase 2 trials and ongoing work on predictive biomarkers to identify responsive patients are central to the program. Full FDA approval for pediatric GHD remains the goal but timing is uncertain.

Why did Merck stop developing it?

The mainstream pharmaceutical narrative isn't fully transparent, but several factors clearly contributed: the lack of functional improvement despite lean mass gains, the insulin sensitivity signal, the hip fracture trial adverse events including CHF, and the difficult regulatory positioning for an aging-related indication (FDA generally resistant to approving drugs for "aging" without disease-specific endpoints). The economic case for a broader indication was insufficient given these complications.

Is the IGF-1 elevation cancer risk meaningful?

For short-term use in healthy individuals without cancer history, the risk is probably modest but uncharacterized. For users with personal or family history of hormone-sensitive cancers (prostate, breast, colorectal), the risk-benefit calculation is meaningfully different. Long-term users should weigh this carefully against their personal medical context.

How does MK-677 compare to peptide GH secretagogues?

The most common comparison is to injectable peptide secretagogues like ipamorelin, GHRP-2, or combinations like CJC-1295 + Ipamorelin. These peptides work through the same GHSR-1a receptor as MK-677 (in the case of ipamorelin and the GHRPs) or through GHRH receptor (in the case of CJC-1295 and sermorelin). The pharmacological differences: MK-677 is oral with a longer half-life producing sustained activation; the peptides are injectable, shorter-acting, and typically dosed multiple times per day. The hormonal endpoints and side-effect profiles overlap considerably, but the practical use profiles differ.

How does it compare to direct GH therapy?

Direct HGH therapy produces large, single-pulse hormone exposure; MK-677 preserves pulsatility but with elevated baseline. Each approach has different pharmacokinetic profiles and somewhat different side-effect distributions, but the core risks (insulin resistance, fluid retention, cancer concerns) are common to all three.

Why is the lethargy/sleep effect so prominent in user reports?

The slow-wave sleep increase is real and documented. For some users this manifests as deeper, more restorative sleep; for others as next-day grogginess. Individual responses to GH and to changes in sleep architecture vary substantially. Morning dosing reduces some of these effects but doesn't eliminate them, given the compound's half-life.

Can the insulin resistance be managed?

In healthy individuals without underlying glucose dysregulation, the effect is typically modest and reversible on discontinuation. Some clinicians use co-administration with metformin or attentive carbohydrate management to mitigate the effect during use. None of this is formally validated for MK-677 specifically, and individual responses vary.

Key Takeaways

1. MK-677 (ibutamoren) is a non-peptide, orally active selective agonist of the ghrelin receptor (GHSR-1a), developed by Merck in the early 1990s as an oral alternative to injectable growth hormone therapy.
2. The compound reliably raises GH and IGF-1 levels in humans to young-adult ranges, while preserving the natural pulsatile pattern of GH secretion. This hormonal effect is the most consistently documented finding across all clinical trials.
3. ⚠️ The Nass 2008 trial in Annals of Internal Medicine — the strongest human evidence — showed clear hormonal effects and increased fat-free mass (1.1 kg over 12 months) but no improvement in strength or physical function despite the body composition change.^[2]
4. ⚠️ Documented adverse effects include decreased insulin sensitivity (rising fasting glucose and HbA1c), fluid retention (mild edema), cortisol elevation (+47 nmol/L), increased appetite and weight gain, and joint discomfort. These are not theoretical — they're measured in well-controlled trials.
5. ⚠️ A Merck-sponsored hip fracture trial showed increased adverse events including congestive heart failure in older patients on MK-677-equivalent doses. This trial was a significant factor in Merck's decision to halt broader development.
6. The IGF-1 elevation associated with MK-677 raises theoretical cancer concerns (epidemiologically, elevated IGF-1 correlates with increased risk of several hormone-sensitive cancers). Direct cancer endpoints have not been adequately characterized in the trials.
7. Regulatorily, MK-677 is not approved anywhere despite having received Orphan Drug Designation from both FDA and EMA in 2017 for pediatric growth hormone deficiency. Development continues as LUM-201 (LUMOS Pharma) for that specific indication only.
8. WADA-prohibited under Class S2. Hair-testing detection methods are now established. For tested athletes, use is a guaranteed violation.
9. Despite frequent labeling as a "peptide" in research-chemical channels, MK-677 is a small molecule. The mislabeling reflects marketing conventions rather than chemical reality.
10. ⚠️ Honest framing: MK-677 has the most substantial human evidence base of nearly any compound in this review series, and that evidence is mixed. The hormonal effects are real. The body composition effects are real but modest. The functional benefits are smaller than expected. The metabolic and cardiovascular safety signals are documented and substantive. This is one of the relatively rare cases where the limiting factor isn't absence of human data — it's the data itself, which suggests a more complicated risk-benefit picture than the marketing implies.

Related Compounds

For peptide-based growth hormone secretagogues that work through the same or complementary pathways, the most direct comparisons are Ipamorelin (selective GHSR-1a agonist, peptide form) and the combination CJC-1295 + Ipamorelin stack. For the broader landscape of growth hormone, GHRH analogs, and endocrine-axis compounds, see the Endocrine Research category.

References